A randomized controlled trial of a therapist-guided online intervention for depressed adults and its utility as an adjunctive to antidepressants and psychotherapy.
Manuel Heinrich, Pavle Zagorscak, Christina Kampisiou, Johannes Bohn, Lars Schulze, Carmen Schaeuffele, Annette Brose, Christine Knaevelsrud
{"title":"A randomized controlled trial of a therapist-guided online intervention for depressed adults and its utility as an adjunctive to antidepressants and psychotherapy.","authors":"Manuel Heinrich, Pavle Zagorscak, Christina Kampisiou, Johannes Bohn, Lars Schulze, Carmen Schaeuffele, Annette Brose, Christine Knaevelsrud","doi":"10.1186/s12888-025-06564-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Internet-based interventions (IBIs) are a low-threshold treatment for individuals with depression. However, comparisons of IBI against unstandardized care-as-usual (CAU) are scarce. Moreover, little evidence is available if IBI has an add-on effect for individuals already receiving an evidence-based treatment such as antidepressants and/or psychotherapy.</p><p><strong>Method: </strong>This parallel, two-arm RCT (1:1 allocation ratio, simple randomization) examines the effectiveness of a therapist-guided cognitive-behavioral IBI compared to unstandardized CAU in a self-selected sample of adults (≥ 18 years). Eligible individuals reported (a) mild (BDI-II score ≥ 14) to moderately severe (PHQ-9 ≤ 19) symptoms of depression, (b) no acute suicidal ideations, (c) no acute or lifetime (hypo-)mania and/or symptoms of psychosis. We assigned eligible individuals to an intervention (INT) arm or an unstandardized CAU-arm (i.e., we imposed no restrictions on what individuals were allowed to do in the 8-week waiting period). Individuals in the INT-arm got access to a 7-module CBT-based IBI. The primary endpoint is depressive symptom load 9 to 11 weeks after randomization. Secondary endpoints included anxiety, self-efficacy, and perceived social support. We report effects for the entire sample (N = 1899), as well as for individuals using the IBI as a stand-alone intervention (n = 1408) or as an add-on to antidepressants (n = 367), psychotherapy (n = 73), or antidepressants and psychotherapy (n = 51). Patients entered the trial with these concurrent treatments (i.e., they were not randomly assigned).</p><p><strong>Results: </strong>Concerning all randomized individuals, 62.5% of individuals in the INT-arm accessed all treatment modules within 11 weeks. Individuals assigned to the INT-arm reported significantly lower depressive symptoms (PHQ-9: - 2.5, 95% CI [- 2.9, - 2.0], d = - 0.7; BDI-II: - 5.3, 95% CI [- 6.5, - 4.1], d = - 0.8) and higher rates of ≥ 50% symptom improvements (PHQ-9: 38.5% vs. 14.3%; BDI-II: 44.6% vs. 14.8%) compared to individuals assigned to the CAU-arm. Secondary outcomes also favored INT over CAU, with effect sizes ranging from |d|= 0.18 (social support) to 0.62 (anxiety). Rates of deterioration (PHQ-9: 4.1%; BDI-II: 3.4%) and self-reported side effects (10.5%) were low in the INT-arm. Similar patterns emerged for all strata. However, the between-arm differences failed to reach significance within the strata of individuals using the IBI as an add-on to psychotherapy.</p><p><strong>Conclusion: </strong>Our results show that providing interested adults access to the therapist-guided, cognitive-behavioral IBI under investigation is associated with improved mental health outcomes, whether individuals use the IBI as a stand-alone or add-on intervention to another evidence-based treatment. This finding aligns with available studies indicating that IBIs should be considered a low-threshold treatment option for individuals with depression.</p><p><strong>Trial registration: </strong>The trial was registered at the Deutsches Studienregister (Trial-Registriation Number/DRKS-ID: DRKS00021106, Date: 25.06.2020).</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"116"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12888-025-06564-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Internet-based interventions (IBIs) are a low-threshold treatment for individuals with depression. However, comparisons of IBI against unstandardized care-as-usual (CAU) are scarce. Moreover, little evidence is available if IBI has an add-on effect for individuals already receiving an evidence-based treatment such as antidepressants and/or psychotherapy.
Method: This parallel, two-arm RCT (1:1 allocation ratio, simple randomization) examines the effectiveness of a therapist-guided cognitive-behavioral IBI compared to unstandardized CAU in a self-selected sample of adults (≥ 18 years). Eligible individuals reported (a) mild (BDI-II score ≥ 14) to moderately severe (PHQ-9 ≤ 19) symptoms of depression, (b) no acute suicidal ideations, (c) no acute or lifetime (hypo-)mania and/or symptoms of psychosis. We assigned eligible individuals to an intervention (INT) arm or an unstandardized CAU-arm (i.e., we imposed no restrictions on what individuals were allowed to do in the 8-week waiting period). Individuals in the INT-arm got access to a 7-module CBT-based IBI. The primary endpoint is depressive symptom load 9 to 11 weeks after randomization. Secondary endpoints included anxiety, self-efficacy, and perceived social support. We report effects for the entire sample (N = 1899), as well as for individuals using the IBI as a stand-alone intervention (n = 1408) or as an add-on to antidepressants (n = 367), psychotherapy (n = 73), or antidepressants and psychotherapy (n = 51). Patients entered the trial with these concurrent treatments (i.e., they were not randomly assigned).
Results: Concerning all randomized individuals, 62.5% of individuals in the INT-arm accessed all treatment modules within 11 weeks. Individuals assigned to the INT-arm reported significantly lower depressive symptoms (PHQ-9: - 2.5, 95% CI [- 2.9, - 2.0], d = - 0.7; BDI-II: - 5.3, 95% CI [- 6.5, - 4.1], d = - 0.8) and higher rates of ≥ 50% symptom improvements (PHQ-9: 38.5% vs. 14.3%; BDI-II: 44.6% vs. 14.8%) compared to individuals assigned to the CAU-arm. Secondary outcomes also favored INT over CAU, with effect sizes ranging from |d|= 0.18 (social support) to 0.62 (anxiety). Rates of deterioration (PHQ-9: 4.1%; BDI-II: 3.4%) and self-reported side effects (10.5%) were low in the INT-arm. Similar patterns emerged for all strata. However, the between-arm differences failed to reach significance within the strata of individuals using the IBI as an add-on to psychotherapy.
Conclusion: Our results show that providing interested adults access to the therapist-guided, cognitive-behavioral IBI under investigation is associated with improved mental health outcomes, whether individuals use the IBI as a stand-alone or add-on intervention to another evidence-based treatment. This finding aligns with available studies indicating that IBIs should be considered a low-threshold treatment option for individuals with depression.
Trial registration: The trial was registered at the Deutsches Studienregister (Trial-Registriation Number/DRKS-ID: DRKS00021106, Date: 25.06.2020).
期刊介绍:
BMC Psychiatry is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of psychiatric disorders, as well as related molecular genetics, pathophysiology, and epidemiology.